Find disease awareness content and relevant supporting materials
Efficacy and safety of elotuzumab for the treatment of multiple myeloma.
Introduction: Multiple myeloma (MM) is the second most common hematologic malignancy and despite significant outcome improvements with novel agents, the majority of patients will eventually relapse and develop treatment resistance.
Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma (ELOQUENT - 1)
The purpose of the study is to determine whether the addition of Elotuzumab to Lenalidomide/low-dose Dexamethasone will increase the progression...
Phase III ELOQUENT-2 study of Empliciti (elotuzumab) plus lenalidomide/dexamethasone shows continued efficacy in multiple myeloma- Bristol-Myers Squibb
Bristol-Myers Squibb presented four-year follow-up data from the Phase III ELOQUENT-2 study in which Empliciti (elotuzumab) plus lenalidomide/dexamethasone (ELd) continued...